- Visibility19
- Citations2
- Sentiment50
- Site quality80
- AI readiness7
AI assistants name Nkarta Therapeutics in 8.3% of answers, which is slightly less often than the typical company in the technology sector at 10%. Its overall score is 31 out of 100, placing it 1,123rd of 2,047 companies. The company's website passes 1 of 14 technical checks for readiness with AI tools.
We asked 15 unbranded questions about the technology market: none named Nkarta Therapeutics. AI assistants named it in 5 of 60 answers (8.3%). The typical technology company is named in 10.0% of answers. By how often it is named, Nkarta Therapeutics ranks 151 of 273 in its sector.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
273 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“Should patients with refractory autoimmune disease consider experimental natural killer cell therapies?”
Patients with refractory autoimmune diseases may consider experimental natural killer (NK) cell therapies, as research and clinical trials are exploring their potential. NK cells are a vital part of the innate immune system, capable of identifying and destroying abnormal cells. In autoimmune diseases, the immune system mistakenly attacks the body's own healthy cells.
Here's a breakdown of why patients might consider these therapies and what the current landscape looks like:
How NK Cell Therapies Work for Autoimmune Diseases:
Many autoimmune diseases are driven by autoreactive B-cells …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 0: Not yet agent-ready. Agents struggle to find basic information about the site.
- 2 of robots.txt, Sitemap, Link headers
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtNot met
Publish a valid robots.txt with crawl rules and a Sitemap line.
- study: 86.8%SitemapNot met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesNot met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 0 of 100 · 97% of checks could run · checked on October 5, 2026 · www.nkartatx.com · 2,047 companies scanned
1 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Not metrobots.txt publishedstudy: 85.0%
- Not metXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
How many times each website was listed as a source in these answers
In the study as US-listed.
- Should patients with refractory autoimmune disease consider experimental natural killer cell therapies?
- Are there insurance coverage options or financial assistance programs for natural killer cell therapy in autoimmune care?
- What is the current clinical trial landscape for natural killer cell therapy targeting autoimmune conditions?
- Which autoimmune diseases are showing the most promise with natural killer cell therapies?
- Is participating in clinical trials for natural killer cell therapy for autoimmune diseases safe and effective?
- What alternative immunotherapies exist for patients not eligible for natural killer cell therapy in autoimmune treatment?
- How is natural killer cell therapy applied in the treatment of multiple sclerosis and other autoimmune diseases?
- Who might benefit most from natural killer cell therapy in the context of autoimmune disorders?
- Natural killer cell therapies vs CAR-T cell therapies for managing autoimmune conditions—how do they differ?
- What factors influence the cost of natural killer cell therapy for autoimmune diseases in the US?
- What challenges might patients experience during natural killer cell therapy for autoimmune disease?
- What are the leading approaches in natural killer cell therapy for autoimmune diseases?
- Which cellular therapies are being explored as alternatives to natural killer cell-based approaches for autoimmune disease?
- How does natural killer cell therapy compare to traditional biologic treatments for autoimmune disorders?
- How can immune-related side effects of natural killer cell treatments be managed in autoimmune patients?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.
A badge of this result that you can show on your own website. Copy the code below.
<a href="https://aeo-audit.rezolve.com/us/nkartatx.com"><img src="https://aeo-audit.rezolve.com/us/badges/nkartatx.com.svg" alt="Overall score 31 of 100, US AI Visibility Study 2026" width="280" height="64"></a>